ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Drug Safety Update MHRA July 2019 PDF.pdf

Drug Safety Update MHRA July 2019 PDF.pdf
Summary: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Rivaroxaban (Xareltoâ–¼): reminder that 15 mg and 20 mg tablets should be taken with food
File Size: 398KB
File Type: application/pdf
Created: 18 July 2019
Last Modified: 18 July 2019